1. Bock J, Covassin N, Somers V. Excessive daytime sleepiness: An emerging marker of cardiovascular risk. Heart. 2022;108:1761-1766. doi:10.1136/heartjnl-2021-319596
2. Dauvilliers Y, Chenini S, Thobois O, et al. Efficacy and safety of sodium oxybate in adults with idiopathic hypersomnia: a randomized controlled trial. Neurology. 2025;104(11):e213690. doi:10.1212/WNL.0000000000213690
3. Heo YA. Calcium, Magnesium, potassium and sodium oxybates (Xywav^®)in sleep disorders: A profile of its use. CNS Drugs. 2022;36:541-549. doi:10.1007/s40263-022-00912-6
4. Morse AM, Dauvilliers Y, Arnulf I, et al. Long-term efficacy and safety of low-sodium oxybate in an open-label extension period of a placebo-controlled, double-blind, randomized withdrawal study in adults with idiopathic hypersomnia. J Clin Sleep Med. 2023;19:1811-1822. doi:10.5664/jcsm.10698
5. Pascoe M, Bena J, Foldvary-Schaefer N. Effects of pharmacotherapy treatment on patient-reported outcomes in a narcolepsy and idiopathic hypersomnia cohort. J Clin Sleep Med. 2019;15:1799-1806. doi:10.5664/jcsm.8088
6. Saad R, Lillaney P, Profant DA, et al. Cardiovascular burden of individuals diagnosed with idiopathic hypersomnia: Real-World Idiopathic Hypersomnia Total Health Model (CV-RHYTHM). Sleep Med. 2025;133:106587. doi:10.1016/j.sleep.2025.106587
7. Saad R, Markt SC, Lillaney P, et al. The clinical and economic burden of idiopathic hypersomnia and narcolepsy: A United States claims-based analysis. Nat Sci Sleep. 2025;17:1809-1823. doi:10.2147/NSS.S498213
8. Thorpy MJ, Krahn L, Ruoff C, Foldvary-Schaefer N. Clinical considerations in the treatment of idiopathic hypersomnia. Sleep Med. 2024;119:488-498. doi:10.1016/j.sleep.2024.05.013

All URLs accessed September 2, 2025